Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure

被引：3

作者：

Gorbunova, M. L. ^{[1
]}

Vilkov, A. V. ^{[2
]}

机构：

[1] Nizhny Novgorod State Med Acad, Nizhnii Novgorod, Russia

[2] Nizhny Novgorod Cardiac Surg Ctr Corall, Nizhnii Novgorod, Russia

来源：

KARDIOLOGIYA | 2016年 / 56卷 / 03期

关键词：

ischemic heart disease; oxidative stress; metabolic therapy; trimetazidine MB;

D O I：

10.18565/cardio.2016.3.67-72

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Study purpose to assess clinical and hemodynamic parameters in patients with ischemic heart disease (IHD) with and without use of metabolic therapy with trimetazidine MB. Materials. Seventy four patients with IHD, 40 of whom in addition to the main therapy for 3 months received metabolic preparation trimetazidine MB. Results. Number of anginal attacks and inhalations of nitroglycerin significantly decreased and parameters of hemodynamics improved after 3 months in patients who received trimetazidine MB. Conclusion. Long-term use of trimetazidine MB in patients with IHD is advisable.

引用

页码：67 / +

页数：6

共 26 条

[1] [Anonymous], 2002, REAMBERIN REALITY PR
[2] [Anonymous], HEART METAB
[3] Belovol A.N., 2012, LU, V5, P51
[4] Chaitman Bernard R., 2004, Journal of Cardiovascular Pharmacology and Therapeutics, V9, pS47, DOI 10.1177/107424840400900105
[5] CIAPPONI A, 2005, COCHRANE DB SYST REV, V19
[6] Trimetazidine: a meta-analysis of randomised controlled trials in heart failure
Gao, Dengfeng
Ning, Ning
Niu, Xiaolin
Hao, Guanghua
Meng, Zhe
[J]. HEART, 2011, 97 (04) : 278 - 286
[7] Guarini G., 2012, HEART METAB, V54, P25
[8] Gurevich K.G., 2006, PHARMATECA, V5, P62
[9] Kalvinsh I., 2002, MILDRONATE MECH ACTI
[10] Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress
Kawano, H
Motoyama, T
Hirai, N
Kugiyama, K
Yasue, H
Ogawa, H
[J]. ATHEROSCLEROSIS, 2002, 161 (02) : 375 - 380

← 1 2 3 →